ProMIS Neurosciences to Showcase PMN310's Ability to Target Toxic Oligomers and Distinguish from Other Amyloid-Beta Oligomers in Preclinical Studies at the 4th International Conference on Cognitive & Behavioral Neurosciences

a week ago

CAMBRIDGE, Massachusetts and TORONTO, Ontario, Sept. 12, 2024 ( GLOBE NEWSWIRE ) -- ProMIS Neurosciences Inc. ( Nasdaq: PMN ) , a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as ...

Ticker	Sentiment	Impact
PMN	Neutral	16 %